Publications: Dr Faraz Mardakheh
DERMIT M, Dodel M, Lee F, Azman M, Schwenzer H, Jones JJL, Blagden S, Ule J et al.(2020).
Subcellular mRNA localization regulates ribosome biogenesis in migrating cells. Developmental Cell
vol. 55,
(3)
298-313.
Yu J, Navickas A, Asgharian H, Culbertson B, Fish L, Garcia K, Olegario JP, Dermit M et al.(2020).
RBMS1 Suppresses Colon Cancer Metastasis through Targeted Stabilization of Its mRNA Regulon. Cancer Discov
vol. 10,
(9)
1410-1423.
Hau HTA, Ogundele O, Hibbert AH, Monfries CAL, Exelby K, Wood NJ, Nevarez-Mejia J, Carbajal MA et al.(2020).
Maternal Larp6 controls oocyte development, chorion formation and elevation. Development (Cambridge)
vol. 147,
(4)
Touat M, Sourisseau T, Dorvault N, Chabanon RM, Garrido M, Morel D, Krastev DB, Bigot L et al.(2018).
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. Journal of Clinical Investigation
vol. 128,
(4)
1671-1687.
Mardakheh FK(2017).
Mass spectrometry analysis of spatial protein networks by colocalization analysis (COLA). Methods in Molecular Biology,
vol. 1636,
Dermit M, Dodel M, Mardakheh FK(2017).
Methods for monitoring and measurement of protein translation in time and space. Molecular BioSystems
vol. 13,
(12)
2477-2488.
Mardakheh FK, Self A, Marshall CJ(2017).
RHO binding to FAM65A regulates Golgi reorientation during cell migration. Development
vol. 144,
(1)
e1.1-e1.1.
Mardakheh FK, Self A, Marshall CJ(2016).
RHO binding to FAM65A regulates Golgi reorientation during cell migration. J Cell Sci
vol. 129,
(24)
4466-4479.
Touat M, Olaussen K, Sourisseau T, Friboulet L, Dorvault N, Enot D, Bigot L, Pontoizeau C et al. (2016).
154 NAMPT inhibition is a novel synthetic lethal therapeutic approach exploiting nuclear–mitochondrial crosstalk in ERCC1-deficient populations. European Journal of Cancer.
vol. 69,
Mardakheh FK, Sailem HZ, Kümper S, Tape CJ, McCully RR, Paul A, Anjomani-Virmouni S, Jørgensen C et al.(2016).
Proteomics profiling of interactome dynamics by colocalisation analysis (COLA). Mol Biosyst
vol. 13,
(1)
92-105.
Natrajan R, Sailem H, Mardakheh FK, Arias Garcia M, Tape CJ, Dowsett M, Bakal C, Yuan Y(2016).
Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology–Genomic Integration Analysis. PLoS Medicine
vol. 13,
(2)
Kümper S, Mardakheh FK, McCarthy A, Yeo M, Stamp GW, Paul A, Worboys J, Sadok A et al.(2016).
Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis. eLife
vol. 5,
(JANUARY2016)
Mardakheh FK, Paul A, Kümper S, Sadok A, Paterson H, Mccarthy A, Yuan Y, Marshall CJ(2015).
Global Analysis of mRNA, Translation, and Protein Localization: Local Translation Is a Key Regulator of Cell Protrusions. Developmental Cell
vol. 35,
(3)
344-357.
Sadok A, McCarthy A, Caldwell J, Collins I, Garrett MD, Yeo M, Hooper S, Sahai E et al.(2015).
Rho kinase inhibitors block melanoma cell migration and inhibit metastasis. Cancer Research
vol. 75,
(11)
2272-2284.
Mardakheh FK, Auciello G, Dafforn TR, Rappoport JZ, Heath JK(2010).
Nbr1 is a novel inhibitor of ligand-mediated receptor tyrosine kinase degradation. Molecular and Cellular Biology
vol. 30,
(24)
5672-5685.
Mardakheh FK, Yekezare M, Machesky LM, Heath JK(2009).
Spred2 interaction with the late endosomal protein NBR1 down-regulates fibroblast growth factor receptor signaling. Journal of Cell Biology
vol. 187,
(2)
265-277.
Sweet SMM, Mardakheh FK, Ryan KJP, Langton AJ, Heath JK, Cooper HJ(2008).
Targeted online liquid chromatography electron capture dissociation mass spectrometry for the localization of sites of in vivo phosphorylation in human Sprouty2. Analytical Chemistry
vol. 80,
(17)
6650-6657.
Mardakheh FK, Yekezare M, Machesky LM, Heath JK (2008).
SPRED redirects activated receptors to lysosomes via scaffolding protein NBR1. European Journal of Cancer Supplements.
vol. 6,
38-39.
Akbarzadeh S, Wheldon LM, Sweet SMM, Talma S, Mardakheh FK, Heath JK(2008).
The deleted in Brachydactyly B domain of ROR2 is required for receptor activation by recruitment of Src. PLoS ONE
vol. 3,
(3)